Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 11
Submit an article Journal homepage
452
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Antihypertensive therapy: from 2003 to 2013 and beyond

Alberto Zanchetti Istituto Auxologico Italiano Professor Emeritus, University of Milan, Via L. Ariosto 13, 20145 Milan, Italy+39 02 61911 2237+39 02 61911 [email protected]
Pages 1443-1446 | Published online: 10 Jan 2014

References

  • No authors listed. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21(6), 1011–1053 (2003).
  • Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J. Hypertens. 31(7), 1281–357 (2013).
  • Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J. Hypertens. 23(6), 1113–1120 (2005).
  • Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 362(9395), 1527–1535 (2003).
  • Black HR, Elliott WJ, Grandits G et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289(16), 2073–2082 (2003).
  • Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290(21), 2805–2816 (2003).
  • Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022–2031 (2004).
  • Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895–906 (2005).
  • ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547–1559 (2008).
  • Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
  • Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
  • Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367(23), 2204–2213 (2012).
  • Gheorghiade M, Böhm M, Greene SJ et al. for the ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309(11), 1125–1135 (2013).
  • Zanchetti A. Evidence and wisdom: recommendations for forthcoming guidelines. J. Hypertens. 29(1), 1–3 (2011).
  • Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 27(5), 923–934 (2009).
  • Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
  • Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 23(12), 2157–2172 (2005).
  • Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur. Heart J. 32(12), 1500–1508 (2011).
  • Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur. Heart J. 31(23), 2837–2840 (2010).
  • The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1575–1585 (2010).
  • Zanchetti A, Liu L, Mancia G et al. Stroke in Hypertension Optimal Treatment (SHOT) trial: protocol and organization. J. Hypertens. 31(e-suppl A), e255 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.